Resources
Primrose Bio Launches Two RNA Polymerases for High-Quality, Low-Cost mRNA
Primrose Bio launched Prima RNApols® Cap AG and Prima RNApols® 7 Pro, two RNA polymerases that improve protein expression, capping efficiency and dsRNA reduction in mRNA production.
Primrose Bio Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Primrose Bio closed a financing round led by new investor Signet Healthcare Partners, with participation from 1315 Capital, Ligand Pharmaceuticals, LDV Partners and Agent Capital.
AMM Ascent 2026
October 28–30, 2026 | Coronado, CA | Presentation and poster
PEGS Europe 2026: Protein & Antibody Engineering Summit
November 16–19, 2026 | Lisbon, Portugal | Poster and booth
14th International mRNA Health Conference 2026
November 17–19, 2026 | Boston, MA | Presentation, poster, and booth
Primrose Bio Awarded NIH Grant to Develop Genetic Medicine Drug Design Technology
A $2 million, 24-month SBIR award from NIH’s NCATS funds development of synthetic noncoding sequence elements to improve DNA- and RNA-based medicines.
BIO International Convention 2026
June 22–25, 2026 | San Diego, CA | Attendee
Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development
Intravacc and Primrose Bio renewed their partnership, pairing PeliCRM197® carrier protein with Intravacc’s conjugation and manufacturing know-how.
PEGS Boston Summit 2026
May 11–15, 2026 | Boston, MA | Presentation, poster, and booth
Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS
A peer-reviewed study in PNAS shows how Function Generator™ combinatorial gene fusion engineers complex microbial traits from tens of millions of gene combinations.
World Vaccine Congress 2026
March 30–April 2, 2026 | Washington, DC | Presentation, poster, and booth
5th Annual Novel Conjugates Summit 2026
March 17–19, 2026 | Boston, MA | Poster
BioProcess International US West (BPI West) 2026
March 9–11, 2026 | San Diego, CA | Poster
PepTalk: The Protein Science and Production Week 2026
January 19–22, 2026 | San Diego, CA | Presentation, poster, and booth
Antibody Engineering & Therapeutics US 2025
December 14–17, 2025 | San Diego, CA | Presentation, poster, and booth
Primrose Bio Launches Prima RNApols Cap AU, a Next-Gen RNA Polymerase for Self-Amplifying mRNA
Prima RNApols Cap AU is an RNA polymerase for self-amplifying mRNA that produces high-yield, fully capped mRNA with less capping reagent and lower dsRNA.
PEGS Europe 2025
November 11–13, Primrose Bio presents and exhibits at PEGS Europe 2025.
Primrose Bio Names Drew Burch as CEO
Drew Burch is appointed CEO and joins the Board. Helge Zieler, PhD, becomes Chief Technology Officer.
mRNA-Based Therapeutics Summit 2025
September 23 – 25, Primrose Bio joins the 2025 mRNA Therapeutics Summit in Boston.
Oxford Nanopore Biopharma Day 2025
June 12, Primrose Bio presented at Oxford Nanopore Biopharma Day in San Diego.
Cytiva’s Process Development Virtual Summit 2025
June 12, Primrose Bio presented at Cytiva’s Process Development Virtual Summit.
Antibody Engineering & Therapeutics Spring Digital Week 2025
May 21, Primrose Bio presented at AET Spring Digital Week.
PEGS US 2025
May 12-16, Primrose Bio presents and exhibits at PEGS Boston 2025.
3rd Annual mRNA Process Development & Manufacturing Summit 2025
May 7, Primrose Bio presented at the 3rd Annual mRNA Process Development & Manufacturing Summit in Berlin.
World Vaccine Congress 2025
April 22–25, Primrose Bio exhibited at the WVC 2025 in Washington, D.C.
Bio-Europe Spring 2025
March 17–19, Primrose Bio was proud to participate in Bio-Europe Spring 2025, held in Italy. Representing the team, Alec Tzianabos connected with global partners to discuss our scalable, efficient, and cost-effective manufacturing solutions for complex biologics. The event provided a valuable forum to share insights and explore collaborations that advance innovation in drug development and design.
JPM 2025: Advancing Biotech Collaboration
January 13-16, Primrose Bio kicked off the year at JPM Week 2025 in San Francisco, where our executive team — Helge Zieler (CEO), Simon Latimer (CFO), Michele Rubino (CBO), and Louis J. Cantolupo (VP of Business Development) — met with partners, investors, and biotech innovators. We had productive conversations focused on solving complex challenges in drug design and manufacturing. It was an energizing start to the year, filled with opportunities for meaningful collaboration and growth.
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
Primrose Bio and Serum Institute of India will develop a novel multi-antigen vaccine, with Primrose Bio building the manufacturing strains using Pfenex Expression Technology.
Primrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA Medicines
Primrose Bio and ExPLoRNA Therapeutics formed a strategic partnership to jointly develop and market products for mRNA medicines.
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
An equity investment from 1315 Capital funds continued development and commercial expansion of Primrose Bio’s manufacturing technologies, including Prima RNApols™.
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Intravacc and Primrose Bio partner on conjugate vaccines, pairing PeliCRM197® carrier protein with Intravacc’s conjugation and manufacturing know-how.
Improving Scale-up Starts With Expression Strategy
Many recombinant protein programs face critical expression challenges long before manufacturing begins. Poor yield, solubility issues, secretion limitations, and uncertain scalability can consume valuable time and resources — making it difficult to know which...
When Your Expression System Isn’t Cooperating With Your Protein
Most biologics teams do not begin development by choosing an expression host from a blank slate.
Strain Engineering & Process Development: A Commercially Proven Platform for Biopharmaceutical Manufacturing
A number of factors contribute to delivering a robust, highly productive, and reliable process for manufacturing a therapeutic protein.
Fab Antibody Fragment Titer Improvement
A partner was developing a Fab fragment to quickly neutralize a therapeutic substrate.
Multimeric VHH Nanobody Expression
VHH single domain antibodies readily express in the Pfenex Expression Technology®.
Rapid Assessment of Fab-VHH Expression Application of the Pfast™ Program for Early-Stage Titer and Activity Screening
Development of a bi-specific antibody derivative: a Fab–VHH fusion.
Pfast™ Lead Identification and Optimization Supporting Computational Drug Discovery Technology
AI generated, humanized Fab from partner
required production and binding assessment.
Development of an Oncology VHH-ADC Candidate via Site-Specific Non-Canonical Amino Acid Conjugation
Incorporate a non-canonical amino acid (ncAA) pAzF, into a VHH antibody for ADC enhancement, PET771.
Recombinant Erwinia Asparaginase Production
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children.
Fusion-Enabled Biosimilar Peptide Teriparatide Expression
Teriparatide, a recombinant PTH (1-34) fragment used in osteoporosis therapy, is a short peptide that can be difficult to express and recover efficiently.
Production of disulfide-rich cow knob domain antibodies: Picobodies™
About 10% of cow antibodies have exceptionally long heavy chain CDR3 regions, including a stalk and knob region.
How Polymerase Selection Improves IVT Outcomes
Self-amplifying RNA (saRNA) manufacturing places stringent demands on in vitro transcription (IVT), particularly for long templates where polymerase processivity, transcript integrity, capping efficiency, yield, and double-stranded RNA (dsRNA) formation directly...
Streamlining Discovery and Development for ncAA Incorporation and Extracellular Protein Production
Streamlining Discovery and Development Workflows Using Engineered P. fluorescens Strains for ncAA Incorporation and Extracellular Protein Production Diane Retallack, President & COO, Primrose Bio at PEGS Boston Summit 2026 Streamlined product discovery and...
Strategies To Reduce mRNA Manufacturing Costs
Manufacturing costs are one of the most pressing challenges facing teams working to scale RNA therapeutic and vaccine pipelines. In vitro transcription, or IVT, relies on several central raw materials, including DNA template, cap analog, nucleotide triphosphates, and...
Presented at the World Vaccine Congress 2026: Extracellular Secretion and Non-canonical Amino Acid (ncAA) Incorporation: New Capabilities Supporting Conjugate Vaccine Discovery and Development
ABSTRACT: Efficient production of vaccine carrier proteins and antigens is paramount to ensuring access to affordable conjugate vaccines. Streamlined conjugation technologies improve product quality and consistency and allow lower antigen input needs. Development of...
Double Stranded RNA Formation And How RNA Polymerase Choice Can Reduce It
Double-stranded RNA is one of those stubborn byproducts that can quietly inflate downstream purification costs and compromise mRNA product quality. In this presentation, Patrik Engström, Principal Scientist at Primrose Bio, breaks down the molecular mechanisms behind...
Presented at the BioProcess International US West (BPI West) 2026: Engineered Fusion Partners Enabling HighYield Recombinant Peptide Production
ABSTRACT: Peptide therapeutics are a fast-growing class of medicines, but traditional solid phase peptide synthesis (SPPS) has limitations in cost, scalability, and environmental impact. Pfenex Expression Technology® (Pfenex) provides an alternative by using a...
Accelerating Antibody Screening with a Scalable Protein Expression Platform
Diane Retallack, President & COO, Primrose Bio at PepTalk: The Protein Science and Production Week at San Diego, CA P. fluorescens-based Pfenex Expression Technology® transforms protein production through combinatorial screening to identify robust strains. With...
Presented at PepTalk The Protein Science and Production Week: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs As an example of the workflow, an Anti-GPCR VHH therapeutic candidate modified to include a single ncAA...
A Rapid, Robust Solution for Accelerating Antibody Screening
A Rapid, Robust Solution for Accelerating Antibody Screening: P. fluorescens-based Pfenex Expression Technology® transforms protein production through combinatorial screening to identify robust strains. With more than 20 years of development and 6 marketed products,...
Presented at Antibody Engineering & Therapeutics US 2025: Overcoming ncAA Production Bottlenecks: High-titer Antibody Expression with 100% pAzF Incorporation at Scale and Minimal Host Toxicity
ABSTRACT: A platform-based approach leveraging the Pfenex Expression Technology® was developed for implementing screening through lead optimization of novel ADCs. As an example of the workflow, an Anti-GPCR VHH therapeutic candidate modified to include a single ncAA...
Presented at PEGS EU 2025: Preclinical Development of a VHH-ADC Using the Pfenex Platform
ABSTRACT: Amber suppression technology has matured over the last 25 years, enabling incorporation of non-canonical amino acids (ncAAs) that allow targeted conjugation and expanded therapeutic functionality. Despite its potential, implementation has been limited by...
Comparable Immunogenicity Observed in Peptides Coupled to PeliCRM197 and KLH in a Murine Model
In this case study, 3 peptides directed to one therapeutic target were conjugated to either CRM197 produced with Pfenex Expression Technology®.
Anti-IL-4 Conjugate Vaccine Prepared with PeliCRM197 is More Immunogenic than KLH Analog
Anti-interleukin 4 (IL-4) conjugate vaccines consist of IL-4 chemically coupled to a carrier protein.
Pfast™ Protein Expression: A Rapid, Robust Solution for Accelerating Biotherapeutic Screening
P. fluorescens-based Pfenex Expression Technology® (Pfenex) transforms protein production through combinatorial screening to identify robust strains. With 20+ years of development and 6 marketed products, Pfenex excels where others fail. Launched in 2024, Pfast™...
Presented at TIDES USA 2025: Advancing mRNA therapeutics with high performance RNA polymerases
ABSTRACT: RNA has emerged as a critical tool in modern biotechnology and therapeutics, with applications ranging from vaccine development to gene therapy. mRNA is synthesized by in vitro transcription using single-subunit RNA polymerases, whose performance directly...
Presented at PEGS US 2025: High-Throughput Expression and Purification of Untagged RNA Polymerase Variants: Advancements in the Pfenex Expression Technology® Platform
ABSTRACT: Primrose Bio's Pfenex Expression Technology® (Pfenex) platform has established itself as a robust, scalable solution for recombinant protein production, as evidenced by its role in six commercially approved products. Integrating sophisticated high-throughput...